Clik here to view.
Icon's quarterly earnings hit by biotech and pharma pullback
Cost and research cuts across biotech and pharma are affecting some of the contracting companies that rely on the industry. Steve Cutler The latest victim is Icon, a Dublin-based contract research...
View ArticleBridgeBio shares promising results in trial of Canavan disease gene therapy
BridgeBio disclosed results Thursday from a Phase 1/2 study of its gene therapy for Canavan disease, an extremely rare and devastating genetic disorder that causes the brain’s white matter to break...
View ArticleCDC advisors decline to recommend RSV shots to younger at-risk adults,...
The CDC’s vaccine policy advisors haven’t budged on new RSV guidance, remaining unconvinced that younger adults at higher risk of disease should get the shot. That was the takeaway from a presentation...
View ArticleSanofi backs fibrosis biotech Agomab as it raises $89M Series D
Agomab Therapeutics is benefiting from Sanofi’s push to become an immunology powerhouse. The Antwerp-based biotech said Friday that the French drug giant and Invus are new investors in its $89 million...
View ArticleClik here to view.
Sanofi reports sales jump for Beyfortus as RSV antibody challenger from Merck...
As Sanofi declares strong early sales for Beyfortus in its second RSV season, the French pharma is confident that it would still come out on top against potential competitor Merck because its antibody...
View ArticleGSK to spend $800M to build two vaccine factories in the US
GSK said it is making its largest manufacturing investment in the US yet, allocating $800 million to upgrade its vaccine production site in Pennsylvania. Two new facilities will double the current size...
View ArticleClik here to view.
Chinook alums reunite following exit to Novartis; The first board appointment...
Tom Frohlich → Tom Frohlich has signed on as CEO of autoimmune disease specialist Jade Biosciences, a company in the Paragon portfolio that raised an $80 million launch round in August. Frohlich...
View ArticleSepterna bags $288M upsized IPO for GPCR drugs
Nascent clinical biotech Septerna added to the slight uptick in IPO fervor this fall with its $288 million Nasdaq listing on Friday. Investors seemed enthused by the prospects of the GPCR biotech. They...
View ArticleClik here to view.
Elucida Oncology shutters due to 'lack of funding'
Elucida Oncology, a clinical-stage biotech led by former Pfizer executive Geno Germano, has shut down, Endpoints News has learned. The New Jersey startup was trying to take a different approach in the...
View ArticleEnGene’s $60M PIPE; AbbVie to develop neuropsychiatric drugs with Gedeon Richter
Plus, news about Tectonic Therapeutic, Molecular Partners and Arcus Biosciences: EnGene snags $60M: The Boston and Montreal gene therapy biotech raised the private placement from new and current...
View ArticleBristol Myers, Ideaya report new data for solid tumors with MTAP deletion
Bristol Myers Squibb and Ideaya Biosciences both released detailed snapshots of early-stage data for cancer drugs targeting solid tumors with a certain mutation known as MTAP deletion. There are no...
View ArticleClik here to view.
Lyell Immunopharma to acquire ImmPACT Bio, cut top programs
Lyell Immunopharma is discontinuing several programs and acquiring CAR-T biotech ImmPACT Bio and its suite of clinical-stage candidates for $30 million in upfront cash and 37.5 million shares of...
View ArticleClik here to view.
Tyra Biosciences gives a first look at its challenge to J&J’s targeted...
Tyra Biosciences unveiled early trial results on its FGFR3-specific inhibitor in advanced bladder cancer patients on Friday, the public company’s first presentation of human data since its inception in...
View ArticleWhy are Lilly and Roche trying to block Novo's deal for Catalent?
This week, Roche joined Eli Lilly in coming out against a deal that would add significant new manufacturing capacity to Novo Nordisk, to help it meet some of the huge demand for its GLP-1 drugs Wegovy...
View ArticleClik here to view.
New radiopharma spinout Rhine Pharma banks on one trial for success, Telix...
The future of Telix Pharmaceuticals’ new spinout Rhine Pharma hinges on the outcome of one early-stage trial, Telix CEO Christian Behrenbruch told Endpoints News in an interview. Christian Behrenbruch...
View ArticleClik here to view.
FDA approves new type of oral antibiotic for UTIs
The FDA has cleared Iterum’s oral antibiotic for certain patients with uncomplicated urinary tract infections (uUTIs) who have limited or no alternative oral options. Orlynvah, also known as oral...
View ArticleHouse Republicans push for more transparency on government-funded trial data
A group of four Republicans on the House Committee on Energy and Commerce called for more transparency of clinical trial data funded by taxpayers after a New York Times story ran this week that said an...
View ArticleHungary's Olivér Várhelyi readies to be EU health commissioner, pledging...
On the heels of her reelection in July, European Commission President Ursula von der Leyen tasked her new commissioner-designate for health and animal welfare with a full plate of pharma-related...
View ArticleRevolution Medicines breaks ground in challenging pancreatic cancer with two...
In an interview Friday, Revolution Medicines CEO Mark Goldsmith, who says he prefers to understate rather than exaggerate, floated a lofty goal: cure pancreatic cancer — or get close. “That’s our aim,...
View ArticleLatest salvo in Pfizer activist fight; John Carroll's Q3 biotech roundup;...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View Article